Display options
Filter resources
Text Availability
Article type
Publication date

Similar articles for PMID: 1922483

Showing 1 to 12 of 28 entries
Sorted by: Best Match Show Resources per page
Reconstitution of long-term T helper cell function after zidovudine therapy in human immunodeficiency virus-infected patients.

Clerici M, Landay AL, Kessler HA, Phair JP, Venzon DJ, Hendrix CW, Lucey DR, Shearer GM.
PMID: 1388195
J Infect Dis. 1992 Oct;166(4):723-30. doi: 10.1093/infdis/166.4.723.

Peripheral blood mononuclear cells from 12 asymptomatic patients infected with immunodeficiency virus (HIV) and 4 patients with AIDS were analyzed before and during therapy with zidovudine for T helper cell (Th) function. Th function improved by more than fourfold...

A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group.

Spector SA, Gelber RD, McGrath N, Wara D, Barzilai A, Abrams E, Bryson YJ, Dankner WM, Livingston RA, Connor EM.
PMID: 7935655
N Engl J Med. 1994 Nov 03;331(18):1181-7. doi: 10.1056/NEJM199411033311802.

BACKGROUND: Serious bacterial infections are common in children infected with the human immunodeficiency virus (HIV). Studies performed before zidovudine became standard therapy found that intravenous immune globulin decreases the number of serious bacterial infections in these children. We designed...

Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.

Cooper DA, Gatell JM, Kroon S, Clumeck N, Millard J, Goebel FD, Bruun JN, Stingl G, Melville RL, González-Lahoz J.
PMID: 8100611
N Engl J Med. 1993 Jul 29;329(5):297-303. doi: 10.1056/NEJM199307293290501.

BACKGROUND: Zidovudine therapy is of benefit in the treatment of symptomatic and asymptomatic human immunodeficiency virus (HIV) infection in persons with CD4+ cell counts of less than 500 per cubic millimeter. The efficacy, safety, and duration of benefit of...

[Recommendation of GESIDA (AIDS Study Group)/National Plan on AIDS with respect to the anti-retroviral treatment in adult patients infected with the human immunodeficiency virus in the year 2000 (I)].

Miró JM, Antela A, Arrizabalaga J, Clotet B, Gatell JM, Guerra L, Iribarren JA, Laguna F, Moreno S, Parras F, Rubio R, Santamaría JM, Viciana P.
PMID: 11109725
Enferm Infecc Microbiol Clin. 2000 Aug-Sep;18(7):329-51.

OBJECTIVE: To update the recommendations for antiretroviral therapy in adult HIV-infected persons according to the new scientific advances and the existence of new antiretroviral drugs in the last two years.METHODS: The antiretroviral therapy recommendations have been condensed by a...

A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy.

Hirsch M, Steigbigel R, Staszewski S, Mellors J, Scerpella E, Hirschel B, Lange J, Squires K, Rawlins S, Meibohm A, Leavitt R.
PMID: 10438352
J Infect Dis. 1999 Sep;180(3):659-65. doi: 10.1086/314948.

A randomized, double-blind, multicenter study of indinavir, zidovudine, and lamivudine was conducted in 320 adults with human immunodeficiency virus type 1 (HIV-1) infection,

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ, Feinberg JE, Balfour HH, Deyton LR, Chodakewitz JA, Fischl MA.
PMID: 9287227
N Engl J Med. 1997 Sep 11;337(11):725-33. doi: 10.1056/NEJM199709113371101.

BACKGROUND: The efficacy and safety of adding a protease inhibitor to two nucleoside analogues to treat human immunodeficiency virus type 1 (HIV-1) infection are not clear. We compared treatment with the protease inhibitor indinavir in addition to zidovudine and...

Survival of patients receiving zidovudine before or after AIDS diagnosis: results of a German multicenter study. German AIDS Study Group.

[No authors listed]
PMID: 8186655
Clin Investig. 1994 Jan;72(2):111-6.

While efficacy of zidovudine (ZDV) in the acquired immunodeficiency syndrome (AIDS) is well established, the issue of survival after early ZDV treatment is still controversial. To assess survival benefits of ZDV treatment prior to AIDS, as compared to treatment...

Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.

Moyle GJ, Bouza E, Antunes F, Smith D, Harris R, Warburg M, Walker M.
PMID: 11327442
Antivir Ther. 1997 Dec;2(4):229-36.

OBJECTIVE: To assess the safety and clinical and immunological activity of zalcitabine/zidovudine combination therapy compared with zidovudine monotherapy in persons with no or limited antiretroviral experience and CD4 counts of 300-500 cells/mm3.DESIGN AND SETTING: A double-blind controlled multi-centre study...

Immunological outcomes of Tenofovir versus Zidovudine-based regimens among people living with HIV/AIDS: a two years retrospective cohort study.

Ayele T, Jarso H, Mamo G.
PMID: 28143541
AIDS Res Ther. 2017 Feb 01;14(1):5. doi: 10.1186/s12981-017-0132-4.

BACKGROUND: Tenofovir (TDF) based regimen was reported to have better immunological outcomes. Unfortunately, there is limited information regarding the immunologic outcome associated with this regimen in Ethiopia, as its routine utilization in this setting begun since 2013.METHODS: A 2...

Natural history of advanced HIV disease in patients treated with zidovudine. The Zidovudine Epidemiology Study Group.

Moore RD, Keruly J, Richman DD, Creagh-Kirk T, Chaisson RE.
PMID: 1503686
AIDS. 1992 Jul;6(7):671-7.

OBJECTIVE: To describe the natural history of advanced HIV disease in patients treated with zidovudine.DESIGN: Longitudinal, observational study.SETTING: Twelve academic and community-based sites.PATIENTS, PARTICIPANTS: Eight hundred and sixty-three patients with AIDS or AIDS-related complex (ARC) with a CD4+ lymphocyte...

Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee.

[No authors listed]
PMID: 7908356
Lancet. 1994 Apr 09;343(8902):871-81.

Concorde is a double-blind randomised comparison of two policies of zidovudine treatment in symptom-free individuals infected with human immunodeficiency virus (HIV): (a) immediate zidovudine from the time of randomisation (Imm); and (b) deferred zidovudine (Def) until the onset of...

Zidovudine therapy, CD4+ and CD8+ counts are associated with a longer survival following AIDS onset.

Fiala M, Swartz J, Teklehaimanot S, Kermani V, Funnye AS, Sayre JW, Gornbein JA.
PMID: 9313205
Lymphology. 1997 Sep;30(3):128-36.

In 60 patients followed from the onset of acquired immunodeficiency syndrome (AIDS) to death, survival was determined by Cox Proportional Hazards Analysis in relationship to seven variables: time-dependent CD4+ and CD8+ peripheral lymphocyte counts, zidovudine treatment, cytomegalovirus (CMV) retinitis,...

Showing 1 to 12 of 28 entries